Company Filing History:
Years Active: 2010-2025
Title: Kenichi Hanada: Innovator in Cancer Treatment
Introduction
Kenichi Hanada is a prominent inventor based in Bethesda, MD (US). He has made significant contributions to the field of cancer research, particularly through his innovative work on synthetic T cell receptors.
Latest Patents
Hanada holds a total of 6 patents. His latest patents focus on anti-thyroglobulin T cell receptors. These patents disclose a synthetic T cell receptor (TCR) that has antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG). The patents also provide related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Additionally, they include antibodies or antigen-binding portions thereof, and pharmaceutical compositions related to the TCRs of the invention. Furthermore, methods for detecting the presence of cancer in mammals and methods for treating or preventing cancer in mammals are also disclosed.
Career Highlights
Kenichi Hanada is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this esteemed institution has allowed him to focus on groundbreaking research that has the potential to impact cancer treatment significantly.
Collaborations
Some of his notable coworkers include Qiong J Wang and James C Yang. Their collaborative efforts contribute to the advancement of research in the field of immunotherapy and cancer treatment.
Conclusion
Kenichi Hanada's innovative work in developing synthetic T cell receptors showcases his commitment to advancing cancer treatment. His contributions are vital in the ongoing fight against cancer, and his patents reflect a promising future for therapeutic interventions.